Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification and characterization of lysophosphatidylcholine 14:0 as a biomarker for drug-induced lung disease.
Saito K, Gemma A, Tatsumi K, Hattori N, Ushiki A, Tsushima K, Saito Y, Abe M, Horimasu Y, Kashiwada T, Mori K, Sato M, Nishiya T, Takamatsu K, Sun Y, Arakawa N, Izumi T, Ohno Y, Saito Y, Hanaoka M. Saito K, et al. Among authors: hanaoka m. Sci Rep. 2022 Nov 17;12(1):19819. doi: 10.1038/s41598-022-24406-z. Sci Rep. 2022. PMID: 36396675 Free PMC article.
C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.
Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Sonehara K, et al. Among authors: hanaoka m. Thorac Cancer. 2023 Feb;14(6):636-642. doi: 10.1111/1759-7714.14798. Epub 2023 Jan 12. Thorac Cancer. 2023. PMID: 36635979 Free PMC article.
Predictive Factors Associated with Long-Term Response to Combination Immunotherapy in Patients with Untreated Advanced Non-Small-Cell Lung Cancer: A Multicenter Retrospective Study.
Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Sonehara K, et al. Among authors: hanaoka m. Oncology. 2023;101(7):425-434. doi: 10.1159/000531324. Epub 2023 Jul 7. Oncology. 2023. PMID: 37423211 Free article.
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study).
Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, Kato A, Yamamoto M, Nishie K, Hama M, Agatsuma T, Kakizaki Y, Yoshiike F, Matsuo A, Chiaki T, Samizo K, Takagi Y, Yamaura M, Hanaoka M, Koizumi T. Araki T, et al. Among authors: hanaoka m. Transl Lung Cancer Res. 2023 Jun 30;12(6):1320-1327. doi: 10.21037/tlcr-23-12. Epub 2023 Jun 15. Transl Lung Cancer Res. 2023. PMID: 37425417 Free PMC article.
Referential equations for pulmonary diffusing capacity generated from the Japanese population using the Lambda, Mu, or Sigma method and their comparisons with prior referential equations.
Hanaoka M, Wada Y, Goto N, Kitaguchi Y, Koarai A, Kubota M, Oyamada Y, Koto H; Clinical Pulmonary Functions Committee of the Japanese Respiratory Society. Hanaoka M, et al. Respir Investig. 2023 Nov;61(6):687-697. doi: 10.1016/j.resinv.2023.07.009. Epub 2023 Sep 15. Respir Investig. 2023. PMID: 37708634 Free article.
554 results